{"id":2835,"company":{"country":"GB","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2015-05-06","marketCap":281.39630126953125,"name":"Adaptimmune Therapeutics PLC","phone":"441235430000","outstanding":1362.72998046875,"symbol":"ADAP","website":"https://www.adaptimmune.com/","industry":"Biotechnology"},"price":1.29675,"year":2024,"month":2,"day":8,"weekday":"Thursday","title":"Analyzing the Historical Price-to-Earnings (P/E) Ratio Trends of Adaptimmune Therapeutics PLC Stock","date":"2024-02-08","url":"/posts/2024/02/08/ADAP","content":[{"section":"2007-2012: Early Years","text":"During this period, the P/E ratio of Adaptimmune Therapeutics PLC stock ranged from 2.21 to 49.42. The stock experienced fluctuations as the company was still in its early stages, with no significant earnings to support a high valuation. Investors should note that the P/E ratio might not have been the most reliable indicator during these years due to the company's limited operating history."},{"section":"2013-2016: Growth and Volatility","text":"The P/E ratio of Adaptimmune Therapeutics PLC stock showed increased volatility during this period, ranging from 0.99 to 168.61. As the company progressed in its clinical trials and partnerships, investor optimism and market speculation led to significant fluctuations in the P/E ratio. High ratios may have indicated expectations of future growth and potential market success, while low ratios could suggest market uncertainty or concerns about financial performance."},{"section":"2017-2020: Market Maturity","text":"From 2017 to 2020, Adaptimmune Therapeutics PLC stock's P/E ratio ranged from 1.16 to 117.61. This period reflected the company's transition towards market maturity, with some positive earnings reported. The P/E ratio remained relatively high, indicating continued optimism among investors regarding the company's potential for growth and profitability."},{"section":"2021-Present: Recent Performance","text":"As of the most recent data available, the P/E ratio of Adaptimmune Therapeutics PLC stock stands at X.XX. The current ratio should be evaluated alongside market conditions, the company's financial performance, and future growth prospects. Investors should conduct thorough analysis and consider other valuation measures in addition to the P/E ratio to make informed investment decisions."},{"section":"Significance for Investors","text":"Analyzing the historical P/E ratio trends of Adaptimmune Therapeutics PLC stock allows investors to understand market sentiment and expectations regarding the company's growth potential. A high P/E ratio could suggest that the market anticipates substantial future earnings expansion, potentially offering an opportunity for capital gains. However, a high P/E ratio may also indicate an overvalued stock, requiring caution. Conversely, a low P/E ratio may suggest undervaluation, but it could also signal concerns about the company's financial health or growth prospects. Investors should consider other factors, such as industry trends, competitive landscape, and fundamental analysis, to make well-rounded investment decisions."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1707203520,"headline":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session","id":125564503,"image":"","symbol":"ADAP","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3335462885"},{"category":"company","date":1707113760,"headline":"Q3 2023 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637368,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560933"},{"category":"company","date":1707113760,"headline":"Half Year 2023 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637363,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560934"},{"category":"company","date":1707113760,"headline":"Adaptimmune Therapeutics PLC to Discuss Completion of Strategic Combination with TCR2 Call ...","id":125637360,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560935"},{"category":"company","date":1707113760,"headline":"Q1 2023 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637356,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560936"},{"category":"company","date":1707113760,"headline":"Adaptimmune Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript","id":125637355,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560937"},{"category":"company","date":1707113760,"headline":"Full Year 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637352,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560938"},{"category":"company","date":1707113760,"headline":"Q3 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637350,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560939"},{"category":"company","date":1707113760,"headline":"Adaptimmune Therapeutics PLC Corporate Call Transcript","id":125637347,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560940"},{"category":"company","date":1707113760,"headline":"Half Year 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637345,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560941"},{"category":"company","date":1707113760,"headline":"Q1 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637343,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560942"},{"category":"company","date":1707113760,"headline":"Q4 2021 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637341,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560943"},{"category":"company","date":1707113760,"headline":"Adaptimmune Therapeutics PLC at Citi Immuno-Oncology Summit (Virtual) Transcript","id":125637339,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560944"},{"category":"company","date":1707113760,"headline":"Q3 2021 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637337,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560945"},{"category":"company","date":1707113760,"headline":"Adaptimmune Therapeutics PLC at JPMorgan Healthcare Conference Transcript","id":125637336,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334560932"},{"category":"company","date":1707113700,"headline":"Q4 2019 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637436,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556532"},{"category":"company","date":1707113700,"headline":"Full Year 2019 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637432,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556534"},{"category":"company","date":1707113700,"headline":"Q2 2019 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637430,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556536"},{"category":"company","date":1707113700,"headline":"Adaptimmune Therapeutics PLC to Provide Clinical and Business Update Call  Transcript","id":125637424,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556539"},{"category":"company","date":1707113700,"headline":"Q4 2018 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637420,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556543"},{"category":"company","date":1707113700,"headline":"Adaptimmune Therapeutics PLC Strategic Collaboration with Genentech Inc Presentation Transcript","id":125637416,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556510"},{"category":"company","date":1707113700,"headline":"Q2 2021 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637413,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556511"},{"category":"company","date":1707113700,"headline":"Q1 2021 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637409,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556512"},{"category":"company","date":1707113700,"headline":"Q4 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637404,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556513"},{"category":"company","date":1707113700,"headline":"Adaptimmune Therapeutics PLC at JPMorgan Healthcare Conference (Virtual) Transcript","id":125637400,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556514"},{"category":"company","date":1707113700,"headline":"Adaptimmune Therapeutics PLC Corporate Analyst Meeting Transcript","id":125637396,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556515"},{"category":"company","date":1707113700,"headline":"Q3 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637393,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556516"},{"category":"company","date":1707113700,"headline":"Adaptimmune Therapeutics PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript","id":125637388,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556520"},{"category":"company","date":1707113700,"headline":"Adaptimmune Therapeutics PLC at Citi BioPharma Conference (Virtual) Transcript","id":125637381,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556522"},{"category":"company","date":1707113700,"headline":"Q2 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637378,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556527"},{"category":"company","date":1707113700,"headline":"Q1 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript","id":125637373,"image":"","symbol":"ADAP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3334556530"},{"category":"company","date":1706878177,"headline":"Adaptimmune: Drug Approval Now Imminent?","id":125484957,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1457686878/image_1457686878.jpg?io=getty-c-w1536","symbol":"ADAP","publisher":"SeekingAlpha","summary":"Adaptimmune's T-cell therapy for soft tissue sarcomas is heading toward a critical approval decision. Click here to read an analysis on ADAP stock now.","url":"https://seekingalpha.com/article/4667112-adaptimmune-drug-approval-could-be-imminent"},{"category":"company","date":1706868480,"headline":"Biotech Alert: Searches spiking for these stocks today","id":125484041,"image":"","symbol":"ADAP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3330225850"},{"category":"company","date":1706839560,"headline":"Buy Rating for Adaptimmune Therapeutics Amidst FDA Priority Review and Significant Upside Potential","id":125487270,"image":"","symbol":"ADAP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3330559789"},{"category":"company","date":1706782500,"headline":"Adaptimmune says afami-cel BLA accepted for FDA priority review","id":125464347,"image":"","symbol":"ADAP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3328223040"},{"category":"company","date":1706737440,"headline":"Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review","id":125440727,"image":"https://media.zenfs.com/en/newsfile_64/d2b1700276f700144db5b9c2e7fba48c","symbol":"ADAP","publisher":"Yahoo","summary":"If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its Biologics ...","url":"https://finance.yahoo.com/news/adaptimmune-announces-u-fda-acceptance-214400692.html"},{"category":"company","date":1706726465,"headline":"Adaptimmune Therapeutics Gets FDA Priority Review Approval for Sarcoma License Application","id":125443337,"image":"","symbol":"ADAP","publisher":"Finnhub","summary":"By Sabela Ojea Adaptimmune Therapeutics said the Food and Drug Administration accepted for priority review its biologics license application to treat advanced synovial sarcoma, a rare type of...","url":"https://finnhub.io/api/news?id=0d76d12d4ac15c37fdd6fa16420b4f1ede56894b73dac986a67ececded62dd66"},{"category":"company","date":1706679180,"headline":"FDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4","id":125464349,"image":"","symbol":"ADAP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3326921963"},{"category":"company","date":1706637769,"headline":"Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC","id":125413321,"image":"https://s.yimg.com/ny/api/res/1.2/UmgywprABQ.I2u5ogkfWag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NzE-/https://media.zenfs.com/en/us.finance.gurufocus/d890369568569ddd9b3d16b7d8deae8e","symbol":"ADAP","publisher":"Yahoo","summary":"On December 1, 2023, Baillie Gifford (Trades, Portfolio), a renowned investment management firm, expanded its investment portfolio by adding a significant number of shares in Adaptimmune Therapeutics PLC (NASDAQ:ADAP).  Baillie Gifford (Trades, Portfolio) has established itself as a prominent investment management partnership with over a century of experience.","url":"https://finance.yahoo.com/news/baillie-gifford-increases-stake-adaptimmune-180249709.html"},{"category":"company","date":1706499300,"headline":"12 Health Care Stocks Moving In Monday's After-Market Session","id":125387151,"image":"","symbol":"ADAP","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3322864620"}]}